# EURTAC: HCP commentary report > 12 HCP sources screened · 210 verified claims from 9 sources · 9 findings. Updated 2026-10-08. ## Report - Trial: Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR - NCT ID: NCT00446225 - Registry: https://clinicaltrials.gov/study/NCT00446225 - Sponsor: Spanish Lung Cancer Group - Phase: Phase 3 - Status: Completed - Drugs: carboplatin, docetaxel, cisplatin - Indications: Non-small cell lung cancer - Version: v1.0.0, edition 1 - Accepted: 2026-10-08 - Last checked: 2026-10-08 - Release hash: b75a07513c2f776240bd399fa7584154ee130c4a28e893ad5b81df97f9204552 ## Counts - HCP commentary sources screened: 12 - Sources cited by verified claims: 9 - Verified claims: 210 - Findings: 9 - People found in screened sources: 30 - People identity-verified: 17 - Voices cited: 16 Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract EURTAC frames a clinician question: should erlotinib or chemotherapy be the initial treatment for advanced non-small cell lung cancer with activating EGFR mutations? Discussion topics include survival interpretation after crossover, historical comparisons, molecular testing, population applicability and reimbursement. Connected treatment questions cover selection among newer regimens, whether and when to intensify therapy, brain metastases and radiotherapy, uncommon mutations, toxicity prevention, specialist referral and administration burden. The account draws on retained public clinician commentary. ## Open Medical Affairs question How should scientific exchange explain the rationale for TKI-first sequencing without converting PFS, response or quality-of-life arguments into a demonstrated overall-survival claim? ## Findings (titles) - F1. TKI-first treatment was favored despite the absence of an overall-survival difference at the time - F2. Timely, interpretable genotyping was treated as a prerequisite for safe treatment selection - F3. Modern intensification preferences were conditional, while predictive selection remained unresolved - F4. Supportive care was integral to the amivantamab option, with anticoagulation duration still questioned - F5. CNS control favored systemic treatment first, but selective local-treatment roles were retained - F6. Historical-control questions exposed unresolved disagreement about mutation-associated prognosis - F7. The common-mutation treatment discussion did not translate into a single approach for uncommon sensitizing mutations - F8. European confirmation was viewed as an access-enabling step, not merely replication of Asian findings - F9. Retrospective commentary emphasized population selection and the provisional nature of clinical understanding ## Sample findings ### F6. Historical-control questions exposed unresolved disagreement about mutation-associated prognosis An audience participant in a YouTube discussion asked whether historical chemotherapy-only groups could establish a survival advantage for erlotinib without EURTAC’s direct comparison. A follow-up question requested numbers for the survival comparison. Source: YouTube video, 2012-10-12. ### F4. Supportive care was integral to the amivantamab option, with anticoagulation duration still questioned An audience participant in a YouTube panel asked when anticoagulation could end for patients taking amivantamab together with lazertinib. Another speaker asked whether anticoagulation should always accompany treatment that does not include amivantamab. Source: YouTube video, 2024-09-07. ## Trial aspects | Aspect | Coverage | Claims | Sources | | --- | --- | ---: | ---: | | EURTAC's first-line TKI-versus-chemotherapy decision | discussed | 14 | 4 | | Molecular work-up before the first-line decision | discussed | 20 | 3 | | Alternative first-line regimens and selection for intensification | discussed | 47 | 2 | | Prevention, referral and administration burden with the amivantamab alternative | discussed | 30 | 2 | | Brain metastases and selective local-treatment roles | discussed | 11 | 1 | | Crossover, historical controls and mutation-associated prognosis | discussed | 10 | 1 | | Boundary of extrapolation to uncommon sensitizing mutations | discussed | 15 | 2 | | European applicability, testing access and historical reimbursement conditions | discussed | 9 | 3 | | Population selection, confirmation and retrospective lessons | discussed | 24 | 1 | | EURTAC-specific molecular follow-up interpretation | assessment incomplete | 0 | 0 | ## Cited sources by channel - Podcasts: 2 - X threads: 2 - YouTube: 5 ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice. - Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing. - 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows. - 5 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up. - 4 further source limits are recorded in the machine-readable scope of this record. - The reviewed public material is not representative of all HCPs. Some recordings were unavailable, and discussions using unnamed or variant references to the trial may be missing. - Publication and upload dates do not establish the exact session or readout date. They also do not demonstrate a change of mind across settings. - Similar content in separate recordings is not counted as independent HCP agreement. Source-native names are retained, and unnamed passages are not assigned to roster participants. - Several survival statements concern the reporting time and crossover interpretation rather than the final status of all later EURTAC analyses. - Approximate or inconsistent numbers remain what speakers said. Bossaer's 0.037 European-study hazard ratio lacks an endpoint in the passage, and his iPASS account explicitly says the 0.48 estimate followed exclusion of EGFR-mutated patients. - Historical approval, access and dosing statements are not current guidance, and individual prophylaxis or toxicity-management practices are not universal protocols. - The original protocol and some linked full-text or regulatory material were unavailable, limiting how completely the underlying evidence can resolve questions raised in the commentary. - The report retains the separate Chinese-study early-use interpretation but does not label that study's estimates as EURTAC results. ## Offer - Size: Focused (9 commentary sources cited) - Current edition: $750. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of weekly updates: $1,300 - 6 months of weekly updates: $1,900 - 12 months of weekly updates: $2,600 - Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (17 now), at most $750; people verified later in the term at no charge - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/eurtac-nct00446225 - Agents: POST https://www.erudio.com/api/orders with {"report": "eurtac-nct00446225", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=eurtac-00446225 ## Cite Erudio Health. EURTAC (NCT00446225): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/eurtac-nct00446225 ## Machine access - JSON: https://www.erudio.com/reports/eurtac-nct00446225.json - MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "eurtac-00446225"}`